Navigation Links
Wyeth Announces Stockholder Approval of Pfizer Merger at 2009 Annual Meeting
Date:7/20/2009

MADISON, N.J., July 20 /PRNewswire-FirstCall/ -- Wyeth (NYSE: WYE) today announced that its stockholders overwhelmingly approved the adoption of its merger agreement with Pfizer (NYSE: PFE) at Wyeth's Annual Meeting of Stockholders. Based on a preliminary vote count by Wyeth's transfer agent, over 98 percent of shares voted favored the merger. Approval of the merger agreement required an affirmative vote of the majority of outstanding shares.

Commenting on the transaction, Bernard Poussot, Wyeth's Chairman, President and Chief Executive Officer, stated: "The merger is in the best interests of our Company and our stockholders. Combined with Pfizer, we see opportunities for increased scale where needed and resources to become the world's premier biopharmaceutical company and an industry leader in human, consumer and animal healthcare, in both disease prevention and treatment. The combined organization will continue Wyeth's mission to bring innovative medical solutions to patients around the world."

Mr. Poussot also said that the Pfizer transaction resulted from recognition of Wyeth's success in research and development and its early entry into biotechnology, which led to $8 billion in revenue from biopharmaceutical and vaccine products in 2008, making Wyeth the fourth largest biotechnology company in the world.

Mr. Poussot also provided an update on the merger integration planning process with Pfizer. "Wyeth is very engaged in the integration planning process and is working with Pfizer to continue the strategies that have led to our successes. Pfizer views this merger unlike others it has done in the past. They are adding entire businesses and capabilities to enable a significant pre
'/>"/>

SOURCE Wyeth
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Trubion Pharmaceuticals Announces Extension of Research Period Under Its Wyeth Collaboration
2. Wyeth Announces Holder Right to Surrender Convertible Debentures
3. Wyeth Declares Common Stock Dividend
4. New Phase 3 Data Continue to Indicate that Wyeths Investigational 13-valent Vaccine Has the Potential to Broaden Coverage Against Pneumococcal Disease
5. Wyeth Sets Webcast and Conference Call For 2009 Second Quarter Earnings
6. Wyeth Announces Full Redemption of $2 Convertible Preferred Stock
7. Wyeth Declares Common and Preferred Stock Dividends
8. Wyeth Sets Webcast and Conference Call for 2009 First Quarter Earnings
9. Wyeth to Present at the SG Cowen & Co. 29th Annual Healthcare Conference
10. Wyeth to Present at the Goldman Sachs Healthcare CEOs Unscripted Conference
11. Wyeth Names Michael Kamarck President, Technical Operations & Product Supply
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... 30, 2015   Aratana Therapeutics, Inc . ... focused on the licensing, development and commercialization of ... that its strategic partner VetStem Biopharma, Inc. has ... of AT-016, an adipose-derived allogeneic stem cell product ... osteoarthritis pain in dogs. The double-blinded, ...
(Date:7/30/2015)... Denmark , July 30, 2015 ... biotechnology company that applies its innovative TransCon technology ... positive top-line results from a six-month Phase 2 ... once-weekly TransCon Growth Hormone in 53 treatment-naïve, pre-pubertal ... "We are extremely pleased with the top-line ...
(Date:7/30/2015)... ... ... part of its 2015 growth plan and as a follow up to the recently announced ... Laboratories is pleased to announce that it has begun construction on a new Microbiological Laboratory. ... be strictly dedicated to basic USP 51, USP 61, and USP 62 testing specific to ...
(Date:7/29/2015)... 2015 Sanofi, un leader ... résultats pour le premier semestre 2015. Le Directeur ... Visionner l,interview vidéo et lire la ... Au sommaire de l,interview :  ... croissance - Diabète - ...
Breaking Biology Technology:Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7Whitehouse Labs Formally Announces Plans to Open a Microbiological Laboratory 2
... GROUND, Md., Jan. 8 Mindful of the ... attacks that followed, Edgewood Chemical Biological Center,s (ECBC) ... technologies and services that address the new world ... flexibility and quality control."We continue to work towards ...
... BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX ) today announced ... Dr. William P. Sheridan, Chief Medical Officer of BioCryst, will ... Healthcare Conference on Thursday, January 15, 2009 at 7:30 a.m. ... 2009 in San Francisco.A link to a live audio Web ...
... 8 Karolinska Development AB (publ),recently closed a ... million,(USD 19 million). Its major shareholders - Karolinska ... Management;,and Praktikerinvest - took their share of the ... million. Karolinska Development was advised by EFG,Bank AB. ...
Cached Biology Technology:ECBC's Environmental BioMonitoring Laboratory Focuses on the Future 2ECBC's Environmental BioMonitoring Laboratory Focuses on the Future 3BioCryst to Present at the J.P. Morgan 27th Annual Healthcare Conference 2BioCryst to Present at the J.P. Morgan 27th Annual Healthcare Conference 3Karolinska Development Closes Fully Subscribed New Share Issue 2Karolinska Development Closes Fully Subscribed New Share Issue 3
(Date:7/31/2015)... , Jul. 31, 2015 NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market and ... has filed provisional patent 62/198989 for ELECTRONIC ... highlights a method to advance crypto-currencies such as Bitcoin ... a common, uniform way to manage all payments.  ...
(Date:7/27/2015)... SAN JOSE, Calif. , July 27, 2015 ... leading developer of human interface solutions, today announced ... ClearPad ® touchscreen solution for its stylish ... controller for its proven reliability, low power and ... with a wet finger. Huawei designers also required ...
(Date:7/23/2015)... , July 23, 2015 Research and ... of the "Global Outlook of the Biometrics ... The global biometrics market is ... and commercial applications owing to the uptake of ... a transformation that enhances the growth of biometrics ...
Breaking Biology News(10 mins):NXT-ID Patents Electronic Crypto-Currency Management Technology 2NXT-ID Patents Electronic Crypto-Currency Management Technology 3NXT-ID Patents Electronic Crypto-Currency Management Technology 4Synaptics Touchscreen Solution Powers New Huawei Watch 2Synaptics Touchscreen Solution Powers New Huawei Watch 3Global Outlook of the Biometrics Industry 2015 2Global Outlook of the Biometrics Industry 2015 3
... from the Bellvitge Biomedical Research Institute (IDIBELL) in ... peculiar class of small non-coding RNAs that are ... messenger RNAs transmit the genetic information required for ... are never translated into proteins and have important ...
... variety of butterflies is responsive to temperature and could be ... leverages more than a century,s worth of museum and weather ... the University of Ottawa combed through Canadian museum collections of ... weather station data going back 130 years. They found butterflies ...
... or listening to someone speak, we construct rich mental models ... actions, events, mental states and contexts. This ability to understand ... of the human mind and central to everyday social life. ... mechanisms that underlie discourse comprehension. The study appears in ...
Cached Biology News:Climate change may disrupt butterfly flight seasons 2Researchers map brain areas vital to understanding language 2
... a protein into cells permits studies of ... apoptotic pathways, and transcription factor-mediated gene regulation. ... effects of a specific protein in a ... directly into the cell. ProteoJuice Protein Transfection ...
... PULSin is an innovative reagent for highly ... cytoplasm of living cells. Unlike DNA transfection, ... the amount and timing of exogenous proteins ... proteins can now be studied. Real ...
... ST-190-XY is an automated instrument with a ... in real-time using light or fluorescence microscopy. ... muscle, and fibroblast cells can be simulated ... X and Y axis of our strain ...
... is a microarray service ... and academic researchers. We are ... Agilent, and we provide expression ... catalogue arrays. Gene expression ...
Biology Products: